Is Gyre Therapeutics, Inc. (GYRE) halal? Halal. Based on AAOIFI screening, Gyre Therapeutics, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 85/100 (Grade: A).
GYRE β Is Gyre Therapeutics, Inc. Halal?
HalalGyre Therapeutics, Inc.
$5.56
-4.30%
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Sector: Healthcare Β· Industry: Biotechnology
Shariah Compliance Status
Based on AAOIFI screening standards
Very Good
Strong compliance across all metrics
Business Activity Screen
PassedChecks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)
Financial Ratio Screen
PassedFinancial ratios must be below AAOIFI thresholds
Compliance History
Halalnow
since Jun 2026
Not Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
Purify Your GYRE Dividends
1.4% non-compliant incomeGYRE has 1.4% prohibited income. Calculate exactly how much of your dividends to donate.
Financial Overview
Market Cap
539.3M
Price
$5.56
Sector
Healthcare
Industry
Biotechnology
More Healthcare Stocks
Track GYRE and 10,000+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.